Gubra A/S (GUBRA.CO)

DKK 374.0

(-2.6%)

EBITDA Summary of Gubra A/S

Gubra A/S's latest annual EBITDA in 2023 was -28.89 Million DKK , down -352.73% from previous year.
Gubra A/S's latest quarterly EBITDA in 2024 Q1 was -11.42 Million DKK , up 4.79% from previous quarter.
Gubra A/S reported an annual EBITDA of 11.16 Million DKK in 2022, down -85.17% from previous year.
Gubra A/S reported an annual EBITDA of 95.39 Million DKK in 2021, up 304.69% from previous year.
Gubra A/S reported a quarterly EBITDA of -11.42 Million DKK for 2024 Q2, down 0.0% from previous quarter.
Gubra A/S reported a quarterly EBITDA of -10.39 Million DKK for 2023 Q1, down -6.87% from previous quarter.

Annual EBITDA Chart of Gubra A/S (2023 - 2020)

Historical Annual EBITDA of Gubra A/S (2023 - 2020)

Year	EBITDA	EBITDA Growth
2023	-28.89 Million DKK	-352.73%
2022	11.16 Million DKK	-85.17%
2021	95.39 Million DKK	304.69%
2020	21.4 Million DKK	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	-11.42 Million DKK	4.79%
2024 Q2	-11.42 Million DKK	0.0%
2023 Q1	-10.39 Million DKK	-6.87%
2023 FY	- DKK	-352.73%
2023 Q3	-12 Million DKK	-15.46%
2023 Q2	-10.39 Million DKK	0.0%
2023 Q4	-12 Million DKK	0.0%
2022 Q2	-2.79 Million DKK	0.0%
2022 Q1	-2.79 Million DKK	0.0%
2022 FY	- DKK	-85.17%
2022 Q3	-9.31 Million DKK	-232.87%
2022 Q4	-9.72 Million DKK	-4.41%
2021 FY	- DKK	304.69%
2020 FY	- DKK	0.0%

Peer EBITDA Comparison of Gubra A/S

Name	EBITDA	EBITDA Difference
ALK-Abelló A/S	913 Million DKK	103.165%
Bavarian Nordic A/S	2.05 Billion DKK	101.408%
Genmab A/S	5.56 Billion DKK	100.52%
Novo Nordisk A/S	113.33 Billion DKK	100.025%
Orphazyme A/S	-26.04 Million DKK	-10.93%
Pharma Equity Group A/S	-24.79 Million DKK	-16.517%
Zealand Pharma A/S	-651.58 Million DKK	95.565%